USPTO serial 79266179
RIBOCYTOKINE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 7, 2020
- Examiner
- GILBERT, REBECCA L
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with RIBOCYTOKINE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,795*
Plus Government fees of $2,125
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Monica Riva Talley
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C.1101 K Street, NW10th FloorWashington, DC 20005Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical agents for laboratory use, in particular nucleic acids, peptides and proteins; chemical agents for the production of anticancer drugs and vaccines, in particular nucleic acids, peptides and proteins | ACTIVE | — |
| 005 | Pharmaceutical products for treating cancerous diseases, infections and autoimmune disorders | ACTIVE | — |
| 040 | Treatment and conversion of material, namely, custom manufacturing of chemical and biochemical preparations; custom manufacturing of biopharmaceuticals, chemical agents for laboratory use, in particular nucleic acids, peptides and proteins, pharmaceutical products of all kinds, in particular for treating cancerous diseases, infections and autoimmune disorders, and of chemical agents for the production of anticancer drugs and vaccines, in particular nucleic acids, peptides and proteins; custom manufacturing of therapeutic pharmaceuticals | ACTIVE | — |
| 042 | Scientific research for medical purposes, in particular for developing treatment concepts for cancerous diseases, infections and autoimmune diseases | ACTIVE | — |
| 044 | Medical and veterinary services in connection with the treatment of cancerous diseases, infections and autoimmune disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BioNTech RNA Pharmaceuticals GmbH
- Other trademarks owned by BioNTech RNA Pharmaceuticals GmbH
- Other trademarks owned by BioNTech SE
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named RIBOCYTOKINE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 7, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jan 31, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 30, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 30, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| May 30, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 30, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 30, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 30, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 19, 2021 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jan 10, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 30, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 29, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 7, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 7, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 21, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 21, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 1, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 19, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 18, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 18, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 18, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 16, 2020 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 12, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 20, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 20, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 13, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 10, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 9, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 9, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 9, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 29, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |